GSK
14.9K posts
GSK
@GSK
We are uniting science, technology and talent to get ahead of disease together.
Our community guidelines: gsk.to/socialmedia
#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy
00:00- #News for #investors & #media: Today at #EASLCongress, we’re presenting results from a phase III trial in chronic hepatitis B, a disease affecting approximately 240 million people globally. Thank you to everyone involved who made this research possible. 🔗 Learn more:
00:00 - #News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/4wPL9f1
00:00 - #News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the Japanese Ministry of Health, Labour and Welfare (MHLW). Learn more: gsk.to/3PKzP3i
00:00 - At #ATS2026, we're sharing findings from 33 research projects across our portfolio of inhaled therapies and biologics – reflecting our ambitious treatment goals, moving beyond symptom control to transform outcomes for people living with chronic respiratory diseases like asthma
00:00 - #News for #investors and #media: At #ATS2026, we’ll be presenting data across 33 abstracts to highlight our research as we work to redefine respiratory care. gsk.to/42ejQxd
00:00 - News for #Investors and #Media Explore the key highlights from our Q1 2026 results announcement ⤵️ Find out more: gsk.to/4uelV7Y $GSK
- Replying to @GSK#Investors and #Media: Cautionary statement regarding forward-looking statements & the definitions & reconciliations for non-IFRS measures in our results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates.
- News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026. Find out more: gsk.to/3OA31JU $GSK #Q1Results
00:00 - #News for #investors and #media: Today we are announcing that our potential first-in-class treatment for chronic hepatitis B has been accepted for regulatory review by the US FDA. It has also received Breakthrough Therapy designation. 🔗 Learn more: gsk.to/4tG7JoC
00:00
